Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-Up Study
Short Study Name (acronym):ACCORDION
Long Name:Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-Up Study
Investigators (list PI first):
William Applegate, MD
Funding Agency:
National Heart Lung and Blood Institute/National Institute on Aging
Funding Dates:
2011 - 2015
Research questions or aims:
- Does a therapeutic strategy that initially targeted an A1C of < 6.0% for a mean of 3.5 years reduce the long-term mean 10 year risk of major CVD events after 6.5 additional years of follow-up compared to a strategy that initially targeted an A1C of between 7 and 7.9%?
- Does a therapeutic strategy that initially used a fibrate to raise HDL-C/lower triglyceride levels and a statin for treatment of LDL-C for a mean of almost 5 years reduce the long-term mean 10 year risk of major CVD events after 5 additional years of follow-up compared to a strategy that only used a statin for treatment of LDL-C?
- Does a therapeutic strategy that initially targeted a systolic blood pressure (SBP) of < 120 mm Hg for a mean of almost 5 years reduce the long-term mean 10 year risk of major CVD events after 5 additional years of follow-up compared to a strategy that targeted a SBP of < 140 mm Hg?
Target population:
The participants will be the same participants recruited as part of the preceding ACCORD study.
Target # to enroll:
The participants will be the same participants recruited as part of the preceding ACCORD study.
Target Dates of enrollment:
Will be contacting and seeing these participants from August 2011 through 2012.
Types of assessments and questionnaires:
Medical history, outcomes questionnaires, physical exam, medications, quality of life questionnaire, blood draw for A1c.
Project Manager Contact Info:
Ashley Widener
Email: awidener@wakehealth.edu
Phone: 336-713-8014